A detailed history of Cerity Partners LLC transactions in Apellis Pharmaceuticals, Inc. stock. As of the latest transaction made, Cerity Partners LLC holds 46,667 shares of APLS stock, worth $1.13 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
46,667
Previous 31,381 48.71%
Holding current value
$1.13 Million
Previous $905,000 64.53%
% of portfolio
0.0%
Previous 0.0%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Feb 13, 2025

BUY
$26.18 - $35.42 $400,187 - $541,430
15,286 Added 48.71%
46,667 $1.49 Million
Q3 2024

Nov 12, 2024

BUY
$28.84 - $41.15 $684,921 - $977,271
23,749 Added 311.18%
31,381 $905,000
Q2 2024

Aug 13, 2024

BUY
$38.07 - $59.71 $127,572 - $200,088
3,351 Added 78.28%
7,632 $292,000
Q1 2024

May 14, 2024

BUY
$55.39 - $72.47 $237,124 - $310,244
4,281 New
4,281 $251,000

Others Institutions Holding APLS

About Apellis Pharmaceuticals, Inc.


  • Ticker APLS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 109,865,000
  • Market Cap $2.67B
  • Description
  • Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...
More about APLS
Track This Portfolio

Track Cerity Partners LLC Portfolio

Follow Cerity Partners LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cerity Partners LLC, based on Form 13F filings with the SEC.

News

Stay updated on Cerity Partners LLC with notifications on news.